Current status of immune checkpoint inhibition in early-stage NSCLC.

Détails

ID Serval
serval:BIB_F6160457AF7A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Current status of immune checkpoint inhibition in early-stage NSCLC.
Périodique
Annals of oncology
Auteur⸱e⸱s
Vansteenkiste J., Wauters E., Reymen B., Ackermann C.J., Peters S., De Ruysscher D.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Statut éditorial
Publié
Date de publication
01/08/2019
Peer-reviewed
Oui
Volume
30
Numéro
8
Pages
1244-1253
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Immune checkpoint inhibition (ICI) immunotherapy has revolutionized the approach to metastatic non-small-cell lung cancer (NSCLC). In particular, antibodies blocking the inhibitory immune checkpoints programmed death 1 (PD-1) and its ligand (PD-L1) are associated with higher response rates, improved overall survival and better tolerability as compared with conventional cytotoxic chemotherapy. Recently, ICI has moved from the second-line to the first-line setting for many patients with non-oncogene-addicted NSCLC, either alone or in combination with chemotherapy. The next logical step is to examine this therapy in patients with non-metastatic NSCLC to improve long-term overall survival and cure rates. For patients with unresectable stage III NSCLC, ICI with durvalumab after concurrent chemoradiotherapy has brought a major improvement in 2-year progression-free and overall survival, which holds promise for an improved cure rate. As the relapse pattern in patients with completely resected early-stage NSCLC is predominantly systemic, high expectations rest on the integration of ICI therapy in their treatment approach. A large number of studies with adjuvant or neo-adjuvant ICI are ongoing and will be discussed here. The advent of stereotactic ablative radiotherapy has brought a valid alternative treatment of patients unfit for or not willing to undergo surgery. Data on combining systemic therapy and stereotactic ablative radiotherapy are virtually non-existent, but there is a strong biological rationale to combine radiotherapy and ICI therapy. Early findings in small feasibility studies are promising and now need to be explored in well-designed phase III trials.
Mots-clé
Antineoplastic Agents, Immunological/pharmacology, Antineoplastic Agents, Immunological/therapeutic use, B7-H1 Antigen/antagonists & inhibitors, B7-H1 Antigen/immunology, Carcinoma, Non-Small-Cell Lung/immunology, Carcinoma, Non-Small-Cell Lung/mortality, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/therapy, Chemoradiotherapy, Adjuvant/methods, Clinical Trials as Topic, Humans, Lung Neoplasms/immunology, Lung Neoplasms/mortality, Lung Neoplasms/pathology, Lung Neoplasms/therapy, Neoadjuvant Therapy/methods, Neoplasm Recurrence, Local/immunology, Neoplasm Recurrence, Local/pathology, Neoplasm Recurrence, Local/prevention & control, Pneumonectomy, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Programmed Cell Death 1 Receptor/immunology, Progression-Free Survival, Radiosurgery, clinical trials, early stage, immunotherapy, non-small-cell lung cancer
Pubmed
Web of science
Open Access
Oui
Création de la notice
18/06/2019 16:43
Dernière modification de la notice
20/06/2020 5:18
Données d'usage